GH Research PLC (GHRS)
12.38
+1.42
(+12.96%)
USD |
NASDAQ |
May 01, 16:00
12.00
-0.38
(-3.07%)
After-Hours: 20:00
GH Research SG&A Expense (Quarterly): 2.837M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.837M |
September 30, 2023 | 2.559M |
June 30, 2023 | 2.679M |
March 31, 2023 | 3.046M |
December 31, 2022 | 2.26M |
September 30, 2022 | 2.001M |
June 30, 2022 | 2.506M |
March 31, 2022 | 3.289M |
Date | Value |
---|---|
December 31, 2021 | 3.268M |
September 30, 2021 | 2.109M |
June 30, 2021 | 0.719M |
March 31, 2021 | 0.448M |
December 31, 2020 | 0.092M |
September 30, 2020 | 0.005M |
June 30, 2020 | 0.003M |
March 31, 2020 | 0.008M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.003M
Minimum
Jun 2020
3.289M
Maximum
Mar 2022
1.739M
Average
2.184M
Median
SG&A Expense (Quarterly) Benchmarks
Amarin Corp PLC | 43.94M |
Jazz Pharmaceuticals PLC | 396.03M |
Prothena Corp PLC | 16.94M |
Iterum Therapeutics PLC | 1.687M |
Mural Oncology PLC | 16.27M |